May 2017- Volume 13, Issue 5

In this Issue

Business & Government Policy

Patent Docs: Laches as a defense to patent infringement felled by Supreme Court

Patent Docs: Laches as a defense to patent infringement felled by Supreme Court

Decision raises the level of diligence drug companies must maintain to best avoid facing patent infringement suits at times when a drug has reached maximum profitability

Doubling down on KRAS

Doubling down on KRAS

Boehringer Ingelheim and Vanderbilt University expand collaboration to tackle difficult-to-treat cancers

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

The chicken or the egg

The chicken or the egg

New study finds high prescription drug costs are not driving up U.S. healthcare costs

For your approval

For your approval

A collection of recent regulatory approvals and other actions globally

Q&A

Q&A: The ethics of germline editing

Q&A: The ethics of germline editing

Cambridge BioMarketing's Dr. Sam Falsetti discusses CRISPR/Cas9 in rare diseases and possibilities for the technology in somatic cell vs. germline editing

Contract Services

Cream of the CRO crop

Cream of the CRO crop

PSI CRO, INC Research, Chiltern among top CROs rated by investigative sites globally in new CenterWatch survey

Plenty of vitality in vaccines

Plenty of vitality in vaccines

INC Research attends World Vaccine Congress, shares recent industry trends

An April acquisition in TNAs

An April acquisition in TNAs

LGC snaps up Axolabs, boosts manufacturing capacity for therapeutic nucleic acids

Picking up the pace

Picking up the pace

PPD advances on a trio of fronts: rare disease, nephrology and HIV

Diagnostics

Hello, hyperpolarized helium MRI

Hello, hyperpolarized helium MRI

New imaging technique could aid in development of improved therapies for CF

Loxo and Ventana set sights on CDx

Loxo and Ventana set sights on CDx

The companies will collaborate to develop and commercialize a pan-TRK IHC test for larotrectinib

Genomic Health reveals Oncotype DX breast cancer test data

Genomic Health reveals Oncotype DX breast cancer test data

New evidence highlights significant impact in reducing burden of unnecessary chemotherapy for patients

Discovery

X- Chem deal-making continues apace

X- Chem deal-making continues apace

Company inks collaboration with Ono Pharmaceutical for oncology target drug leads

Switching genes to fight addiction

Switching genes to fight addiction

Drugs can change epigenetics, a finding that could inform drug discovery

Faster than Prozac

Faster than Prozac

UCSD researchers find GLO1 quickly alleviates depression in mice

Lhasa and Optibrium enter research and product development collaboration

Lhasa and Optibrium enter research and product development collaboration

Drug discovery software specialists combine expertise to extend studies into drug metabolism modeling

MicroRNA inhibitors halt cancer cell growth

MicroRNA inhibitors halt cancer cell growth

TSRI research says small-molecule RNA inhibitors can target and kill specific types of cancer

Research & Development

Potential colon carcinoma cure

Potential colon carcinoma cure

Small-molecule compounds demonstrate tumor regression and adaptive immune response

As good as the real thing?

As good as the real thing?

Organovo shares bioprinted kidney tissue data and celebrates review of their bioprinted liver tissue

A CNS collaboration

A CNS collaboration

nLife, WAVE Life Sciences team up for the first time on nucleic-acid therapeutics

‘Disruptive’ technology to find synergistic drug combos

‘Disruptive’ technology to find synergistic drug combos

Pharnext announces R&D agreement with Galapagos to generate a new pipeline of synergistic drug combinations

New treatment potential for some breast cancers

New treatment potential for some breast cancers

PARP inhibitors may be able to treat more breast cancer subtypes than previously thought

Clinical Trials

Linking predictive biomarkers to clinical trials

Linking predictive biomarkers to clinical trials

BMS, Foundation Medicine focus on such markers as tumor mutational burden, microsatellite instability

Adding AI to the mix

Adding AI to the mix

CGI teams up with Mendel Health to better match patients with clinical trials

A quick antibiotic response

A quick antibiotic response

Paratek’s omadacycline shows promise as broad-spectrum treatment for community-acquired infections

The new way to the heart?

The new way to the heart?

Analysis shows Novartis’ Entresto improves glycemic control in heart failure patients with diabetes

Preclinical

Heat reports ComPACT therapy data

Heat reports ComPACT therapy data

Poster presented at AACR meeting shows positive data for combination immunotherapy

Envigo covers all the R&D bases

Envigo covers all the R&D bases

Company rolls out new animal and non-animal technologies; at least five new in-vitro tests to be introduced ahead of CiPA recommendations

Making sense of mitochondria

Making sense of mitochondria

Luxcel Biosciences and HD Biosciences team up on new assay technology for mitochondria toxicity and metabolism

Putting some muscle behind SMA treatment

Putting some muscle behind SMA treatment

Preclinical trial of CK-2127107 shows improved muscle function in mouse models of spinal muscular atrophy

Editor's Focus

Put your money where your science is

Put your money where your science is

It is good news that NIH, FDA and CDC all got funding boosts in the latest omnibus appropriations legislation, but that should be a foregone conclusion, not something we have to wonder about each and every year

Commentary

Out of order: (Not a) Goo goo g’job

Out of order: (Not a) Goo goo g’job

Regardless of whether it's passive neglect or active erasure, we need to stop leaving out non-Caucasian populations when it comes to cancer research, genome studies and treatment

Guest Commentary: CRISPR--The past, present and future

Guest Commentary: CRISPR--The past, present and future

The associate director in the Product Management group at Taconic Biosciences takes a look at where CRISPR has been, where it is now, where it is going and what that could all mean for getting the most out of this popular gene-editing technology

Special Reports

Special Focus: A crisper picture with CRISPR

Special Focus: A crisper picture with CRISPR

CRISPR/Cas9 gene-editing technology continues to make strides in life sciences
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue  

• Volume 17 • Issue 6 • June 2021

June 2021

June 2021 issue